Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).

Landsmeer-Beker, E A; Massa, G G; Maaswinkel-Mooy, P D; van de Kamp, J J; Papapoulos, S E

Landsmeer-Beker, E A; Massa, G G; Maaswinkel-Mooy, P D; van de Kamp, J J; Papapoulos, S E.

Affiliation

Landsmeer-Beker EA; Department of Paediatrics, University Hospital Leiden, The Netherlands.

Eur J Pediatr ; 156(10): 792-4, 1997 Oct.

Article in En | MEDLINE | ID: mdl-9365071

Subject(s)

Diphosphonates/administration & dosage; Osteogenesis Imperfecta/drug therapy; Body Height/drug effects; Bone Density/drug effects; Child; Diphosphonates/adverse effects; Follow-Up Studies; Humans; Infant; Long-Term Care; Male

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteogenesis Imperfecta / Diphosphonates Type of study: Observational_studies / Prognostic_studies Limits: Child / Humans / Infant / Male Language: En Journal: Eur J Pediatr Year: 1997 Document type: Article Affiliation country: Netherlands

Search on Google

Add to My VHL

XML

PubMed Links